fda status bpc-157 compounding pharmacies 2026 Big news for the peptide space. The Pharmacy Advisory Committee recently voted eight to six in favor of allowing compounding to produce BPC 157. Here is what you need Big decisions could be coming
Big decisions could be coming for peptide compounding. Over the next few days, the FDA's Pharmacy Compounding Advisory Committee will discuss several peptides, including BPC 157, and whether they should be considered for FDA's July 2026 Peptide Compounding Meeting: What PCAC Could Change for BPC 157, TB 500, Semax, and More PeptideKnow 3 FOR 3. An FDA advisory committee has now voted 86, with one abstention, to recommend BPC 157, KPV and TB 500 for inclusion on the 503A Bulks List. This is not FDA approval Exciting news for peptides coming out of today's committee hearing! The FDA Pharmacy Compounding Advisory Committee voted 8 6 to recommend adding BPC 157 to the 503A Bulks List for use in compounding for 83% of peptide aware Americans want the FDA to make peptides more accessible AOL
Pay in 4 interest-free payments of $5.79 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Aug 4 - Aug 9

